RELYVRIO

Peak

sodium phenylbutyrate; taurursodiol

Amylyx Pharmaceuticals

NDAORALFOR SUSPENSIONPriority Review

Approved

Sep 2022

Lifecycle

Peak

Competitive Pressure

0/100

Loss of Exclusivity

LOE Date

Jul 27, 2040

175 months away

Patent Expiry

Jul 27, 2040

Exclusivity Expiry

Sep 29, 2029

Patent Records (5)

Patent #	Expiry	Type	Use Code
10251896	Dec 24, 2033		U-3460
10857162	Dec 24, 2033		U-3460
11071742	Dec 24, 2033	Product	—
9872865	Dec 24, 2033		U-3460
11583542	Jul 27, 2040	Product	—

Company

Amylyx Pharmaceuticals

External Resources

Full prescribing information

FDA approval history